Date:9/30/2010

eivable (11,000) (11,000) Retained earnings 92,797,859 67,888,667 Statutory reserves 3,253,878 3,253,878 Accumulated other comprehensive income 7,617,703 6,523,602 Total shareholders' equity 134,517,057 126,063,376 Total liabilities and shareholders' equity $202,340,274 $168,742,463 JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.) CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (Unaudited) For the For the Three Months Ended Twelve Months Ended June 30, June 30, 2010 2009 2010 2009 REVENUES: Sales $29,308,512 $31,152,620 $97,443,897 $117,143,950 Sales- related parties -- 83 -- 244,026 TOTAL REVENUES, net 29,308,512 31,152,703 97,443,897 117,387,976 Cost of sales 8,195,200 8,149,727 26,097,103 27,854,747 Cost of sales - related parties -- 19 -- 54,519 COST OF SALES 8,195,200 8,149,746 26,097,103 27,909,266 GROSS PROFIT 21,113,312 23,002,957 71,346,794 89,478,710 RESEARCH AND DEVELOPMENT EXPENSE 1,100,700 1,099,875 4,400,100 4,395,000 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 5,331,689 4,203,777 18,731,844 35,315,529 INCOME FROM OPERATIONS 14,680,923 17,699,305 48,214,850 49,768,181 OTHER (INCOME) EXPENSE, NET: Change in fair value of derivative liabilities (1,141,384) -- (14,631,455) -- Non-operating expense (income), net 162,061 (257,927) 382,122 804,561 Non-operating expense (income) - related party (80,718) (69,694) (322,674) (382,970) Interest expense, net 4,233,550 1,760,543 19,796,531 5,904,511 Loss from discontinued operations 43,023 88,116 243,792 1,781,946 OTHER EXPENSE, NET 3,216,532 1,521,038 5,468,316 8,108,048 INCOME BEFORE PROVISION FOR INCOME TAXES 11,464,391 16,178,267 42,746,534 41,660,133 PROVISION FOR INCOME TAXES 4,278,118 4,686,549 12,896,179 12,779,869 NET INCOME $7,186,273 $11,491,718 $29,850,355 $28,880,264 OTHER COMPREHENSIVE INCOME: Unrealized gain (loss) on marketable securities 77,843 633,412 166,378 (1,514,230) Foreign currency translation adjustment 730,330 (41,357) 92
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results